Sanofi
SNYHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeSanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. The $103.41B market capitalization puts SNY squarely in large-cap range for its industry. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Market Cap
$103.41B
Beta
0.28
P/E (TTM)
22.95
P/E (Fwd)
7.96
EPS (TTM)
$1.88
EPS (Fwd)
$5.42
ROE
5.7%
ROA
5.1%
Cash
$6.35B
Total Debt
$23.58B
Free CF
$6.30B
52W Change
-6.2%
Annual Financials
Cash vs Debt
Where SNY stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SNY finished 1.37% above its 150-day moving average ($43.87) and 0.20% above its 200-day moving average ($44.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SNY overbought or oversold?
At the September 3, 2026 close, SNY's RSI(14) was 55.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $6.35B in cash, though total debt stands at $23.58B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $6.30B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 5.7%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $40.56B to $46.72B.
With a beta below 0.7, Sanofi typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing SNY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.